JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

10.13 -3.71

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.12

Max

10.32

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.1M -17M
Darbuotojai	55
EBITDA	4.7M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+41.91% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	223M 596M
Ankstesnė atidarymo kaina	13.84
Ankstesnė uždarymo kaina	10.13

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-30 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

2026-01-30 23:47; UTC

Įsigijimai, susijungimai, perėmimai

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

2026-01-30 23:41; UTC

Rinkos pokalbiai

Deckers Outdoor Seen as Undervalued -- Market Talk

2026-01-30 23:12; UTC

Įsigijimai, susijungimai, perėmimai

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

2026-01-30 22:20; UTC

Uždarbis

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

2026-01-30 22:10; UTC

Rinkos pokalbiai

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

2026-01-30 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-01-30 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-30 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-30 21:42; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

2026-01-30 21:36; UTC

Uždarbis

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

2026-01-30 21:33; UTC

Uždarbis

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

2026-01-30 20:42; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

2026-01-30 20:37; UTC

Įsigijimai, susijungimai, perėmimai

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

2026-01-30 20:20; UTC

Rinkos pokalbiai

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

2026-01-30 20:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

2026-01-30 19:52; UTC

Uždarbis

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

2026-01-30 19:29; UTC

Rinkos pokalbiai

Uždarbis

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

2026-01-30 19:09; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-30 19:09; UTC

Rinkos pokalbiai

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

2026-01-30 19:07; UTC

Rinkos pokalbiai

Canada Performing Well Below Economic Potential -- Market Talk

2026-01-30 18:46; UTC

Uždarbis

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

2026-01-30 18:34; UTC

Uždarbis

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

41.91% į viršų

12 mėnesių prognozė

Vidutinis 15 USD 41.91%

Aukščiausias 18 USD

Žemiausias 13 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.